TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8964192

Group type: EXPERIMENTAL
Intervention: Antiatherosclerosis interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard lipids (total cholesterol and LDL-cholesterol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triglyceride-rich lipoproteins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial coronary angiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasonographic measures of carotid intima-media thickness
Number of subjects: 0
Study: 8173309

Group type: EXPERIMENTAL
Intervention: 0.15 IU rhGH/kg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.30 IU rhGH/kg/day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 0.075 IU rhGH/kg/day
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3815173

Group type: EXPERIMENTAL
Intervention: Abdominopelvic computerized tomography
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Open peritoneal lavage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 30

Group type: COMPARATOR
Intervention: Negative findings on laparotomy
Number of subjects: 30
Study: 31944084

Group type: EXPERIMENTAL
Intervention: Endophytic rhizobacteria treatment
Number of subjects: 10
Study: 30093516

Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation package (patient‐held information workbook, goal‐setting diary, and up to six additional therapy sessions)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual rehabilitation care (control)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Enhanced rehabilitation package
Number of subjects: 61
Study: 28003026

Group type: EXPERIMENTAL
Intervention: Nurse-led OA clinic training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-training questionnaire
Number of subjects: 0
Study: 25343577

Group type: EXPERIMENTAL
Intervention: Postural mimicry by the virtual interaction partner during a conversation about a sensitive conflict issue
Number of subjects: 60

Group type: COMPARATOR
Intervention: Counter-mimicry condition
Number of subjects: 60
Study: 22642755

Group type: EXPERIMENTAL
Intervention: Structured programme of dietary advice over 24 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Structured programme of dietary advice
Number of subjects: 27
Study: 20860572

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 34
Study: 19083390

Group type: EXPERIMENTAL
Intervention: Mixed rice (BRBL group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: White rice (WR group)
Number of subjects: 40
Study: 16824240

Group type: EXPERIMENTAL
Intervention: S(+) ketamine (0.05 mg kg‐1, 1.0 mL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl (25 microg, 1.0 mL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.9% saline (1.0 mL)
Number of subjects: 90
Study: 12865483

Group type: EXPERIMENTAL
Intervention: Treatment of hypertension in subjects aged 80 years and older
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreatment of hypertension in those aged 80 years and older
Number of subjects: 0
Study: 11291605

Group type: EXPERIMENTAL
Intervention: C4 serum concentration in hypertensive patients
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IgA, IgG, IgM serum concentrations in hypertensive patients
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Duration of hypertension
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: C4 serum concentration
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: IgA, IgG, IgM immunoglobulins
Number of subjects: 81
Study: 8780336

Group type: EXPERIMENTAL
Intervention: Formula PO/S (53% palm olein and 47% soy oil)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Formula S/C (60% soy oil and 40% coconut oil)
Number of subjects: 11
Study: 1502399

Group type: EXPERIMENTAL
Intervention: Food-intake related factors
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (234 controls)
Number of subjects: 234
Study: 6838744

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 2-3.5 ml
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: heavy cinchocaine
Number of subjects: 33
Study: 30786754

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg for the first 4 weeks, then force-titrated to 25 mg until week 24)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 29856004

Group type: EXPERIMENTAL
Intervention: AZD5069 (0.1-200 mg single dose or 10-120 mg multiple doses)
Number of subjects: 240

Group type: COMPARATOR
Intervention: AZD5069 (high-fat, high-calorie meal effect)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: AZD5069 (twice-daily dosing)
Number of subjects: 240

Group type: COMPARATOR
Intervention: AZD5069 (age effect)
Number of subjects: 240

Group type: COMPARATOR
Intervention: AZD5069 (ethnicity effect)
Number of subjects: 240

Group type: COMPARATOR
Intervention: AZD5069 (co-administration with ketoconazole)
Number of subjects: 240

Group type: COMPARATOR
Intervention: AZD5069 (various formulations)
Number of subjects: 240
Study: 27599475

Group type: EXPERIMENTAL
Intervention: BMI z-scores in pre-menarcheal girls
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: BMI and height in girls aged 13-14 years who reached menarche
Number of subjects: 533
Study: 27129007

Group type: EXPERIMENTAL
Intervention: Test formulation of allopurinol (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation of allopurinol (200 mg)
Number of subjects: 24
Study: 22650250

Group type: EXPERIMENTAL
Intervention: Wireless capsule pH‐metry (WC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard nasal pH catheter (SC)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: ESM + WC
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: EGD + WC
Number of subjects: 86

Group type: COMPARATOR
Intervention: ESM + SC
Number of subjects: 86
Study: 21048707

Group type: EXPERIMENTAL
Intervention: Oral microdose of (14)C-labeled acetaminophen (AAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 0
Study: 17907648

Group type: EXPERIMENTAL
Intervention: Numerical scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal rating scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual analogy scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face scale
Number of subjects: 0
Study: 15714423

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 0
Study: 12484676

Group type: EXPERIMENTAL
Intervention: Expert tutors (defined by previous tutorial experience)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonexpert tutors
Number of subjects: 0
Study: 9484756

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at a dose of 800 mg/day, then 1200 mg/day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 7648765

Group type: EXPERIMENTAL
Intervention: E3810 (20 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2541637

Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 50 micrograms
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 100 micrograms
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 150 micrograms
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe) 200 micrograms
Number of subjects: 18
Study: 358021

Group type: EXPERIMENTAL
Intervention: Vincamine hydrochloride, administered intramuscularly for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dihydrogenated ergotoxine derivative, administered intramuscularly for 10 days
Number of subjects: 20
Study: 31181221

Group type: EXPERIMENTAL
Intervention: Home visits (HVs) by community health workers (CHWs) over 6 months
Number of subjects: 301

Group type: COMPARATOR
Intervention: Usual care and portal training only
Number of subjects: 301
Study: 28218553

Group type: EXPERIMENTAL
Intervention: Support from family, friends, and health professionals
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Cleft-related comments and/or teasing
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Concerns about child's future
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Psychological support
Number of subjects: 356
Study: 25956401

Group type: EXPERIMENTAL
Intervention: Bilateral arm ischemic preconditioning (BAIPC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham BAIPC (Control)
Number of subjects: 58
Study: 22753810

Group type: EXPERIMENTAL
Intervention: ID-verify alert
Number of subjects: 4028

Group type: EXPERIMENTAL
Intervention: ID-reentry function
Number of subjects: 4028

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4028
Study: 20658222

Group type: EXPERIMENTAL
Intervention: Psychosocial training for speech therapists
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 23
Study: 19101421

Group type: EXPERIMENTAL
Intervention: Difluprednate 2 times a day
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Difluprednate 4 times a day
Number of subjects: 438

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 438
Study: 16478927

Group type: EXPERIMENTAL
Intervention: Endodontic Decision Board (EndoDB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care (standard discussion and informed consent process)
Number of subjects: 67
Study: 15351795

Group type: EXPERIMENTAL
Intervention: Gliclazide (20 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nateglinide (270 mg/day, 90 mg t.i.d.)
Number of subjects: 24
Study: 11018853

Group type: EXPERIMENTAL
Intervention: Addition of 3TC to ZDV + ddI or ZDV + ddC (addition arm)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Switch to ZDV + 3TC therapy (switch arm)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Continuation of ZDV + ddI or ZDV + ddC (continuation arm)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 325
Study: 9067043

Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 7 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 15 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 30 min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lidocaine tape applied for 60 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 30
Study: 8339870

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg daily for 4 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3825912

Group type: EXPERIMENTAL
Intervention: 300 to 400 mg 3‐OHQ orally
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 150 mg quinidine base intravenously
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of 300 to 400 mg 3‐OHQ orally and 150 mg quinidine base intravenously
Number of subjects: 5
Study: 28549592

Group type: EXPERIMENTAL
Intervention: Collaborative pharmacist-physician medication therapy management (MTM) program
Number of subjects: 178

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 178
Study: 27836513

Group type: EXPERIMENTAL
Intervention: Nadroparin (171 UI/kg, subcutaneously, once a day)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%, subcutaneously, once a day)
Number of subjects: 259
Study: 25534209

Group type: EXPERIMENTAL
Intervention: Implementation of a CDSS
Number of subjects: 1316
Study: 22425375

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) - 1500 pulses, 8 Hz, 3 bars, 4 sessions once a week
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 79
Study: 20388647

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg every other day to 50 mg daily, adjusted based on serum potassium)
Number of subjects: 3100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3100
Study: 19278083

Group type: EXPERIMENTAL
Intervention: 1.14% SMFP calcium carbonate-based dentifrice
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: 1.14% SMFP silica-based dentifrice
Number of subjects: 998

Group type: COMPARATOR
Intervention: Non-fluoride calcium carbonate-based dentifrice
Number of subjects: 998
Study: 16468962

Group type: EXPERIMENTAL
Intervention: TAC-SRL2 mg
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: TAC-SRL0.5 mg
Number of subjects: 975

Group type: COMPARATOR
Intervention: TAC-MMF
Number of subjects: 975
Study: 12714091

Group type: EXPERIMENTAL
Intervention: Beef consumption
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Chicken consumption
Number of subjects: 61
Study: 10961218

Group type: EXPERIMENTAL
Intervention: Helical CT (VAR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional CT (sequential mode)
Number of subjects: 50
Study: 8928758

Group type: EXPERIMENTAL
Intervention: GH (0.3 mg.kg‐1.day‐1 sc)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: IGF‐I (80 micrograms.kg‐1.day‐1 sc)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (saline sc)
Number of subjects: 26
Study: 1336292

Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 3882269

Group type: EXPERIMENTAL
Intervention: Tiapamil (1 mg/kg followed by 25 micrograms/kg/min over 36 hr)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 29020467

Group type: EXPERIMENTAL
Intervention: Fractional picosecond 1,064 nm laser plus 4% hydroquinone cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4% hydroquinone cream only
Number of subjects: 30
Study: 25900347

Group type: COMPARATOR
Intervention: 3 g daily of placebo gel applied topically + periodontal debridement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 g daily of a 15% Mtz benzoate gel applied topically + periodontal debridement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 750 mg Mtz (Flagyl(®)) daily single dose + periodontal debridement
Number of subjects: 30
Study: 24793627

Group type: EXPERIMENTAL
Intervention: Complementary axillary lymph node dissection (ALND) with positive sentinel node
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 0
Study: 22594373

Group type: EXPERIMENTAL
Intervention: The Practical Guide of PE (bibliotherapy)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 421
Study: 20127212

Group type: EXPERIMENTAL
Intervention: Subcutaneous indwelling vacuum drainage
Number of subjects: 111

Group type: COMPARATOR
Intervention: Intraarticular indwelling vacuum drainage
Number of subjects: 111
Study: 18540740

Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication (withdrawn onto pill-placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication continuation
Number of subjects: 0
Study: 16287349

Group type: EXPERIMENTAL
Intervention: CE (Concentric and Eccentric phases)
Number of subjects: 47

Group type: COMPARATOR
Intervention: CT (Control group)
Number of subjects: 47
Study: 12351550

Group type: EXPERIMENTAL
Intervention: Laser-assisted ICSI (LA-ICSI)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional ICSI (C-ICSI)
Number of subjects: 32
Study: 10202604

Group type: COMPARATOR
Intervention: Estradiol (E2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 12
Study: 7594103

Group type: EXPERIMENTAL
Intervention: Low dose sematilide (0.75 then 0.3 mg/min)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High dose sematilide (1.5 then 0.6 mg/min)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Neither low nor high dose sematilide
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High dose sematilide
Number of subjects: 39
Study: 2316419

Group type: EXPERIMENTAL
Intervention: NHS nursing homes
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hospital wards
Number of subjects: 9
Study: 7367152

Group type: EXPERIMENTAL
Intervention: Training program designed to promote self‐generation of strategies using self‐verbalization
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal training program of the centre
Number of subjects: 41
Study: 30741884

Group type: EXPERIMENTAL
Intervention: Nomogram predicting risk of interventions for bleeding after high-grade renal trauma
Number of subjects: 326
Study: 27841822

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.01 to 0.06 U/min)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Norepinephrine (10 to 60 μg/min)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 300

Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 300
Study: 26231757

Group type: EXPERIMENTAL
Intervention: EAT intervention delivered by dietitians during usual consultations, based on behaviour change counselling methods including motivational interviewing and cognitive-behavioural therapy.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control condition providing treatment as usual before switching to EAT intervention.
Number of subjects: 400
Study: 24169061

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol at 320 micrograms/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21507143

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance for antibiotic treatment
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (current guidelines for antibiotic treatment)
Number of subjects: 172
Study: 19476770

Group type: EXPERIMENTAL
Intervention: Oral discussion and written pamphlet outlining the risks of the procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional oral dialogue of the surgical risks
Number of subjects: 100
Study: 17297625

Group type: EXPERIMENTAL
Intervention: Severe Intermittent Hypoxia (SIH) - 12% O2 for 1 h/day, 5 days/week for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate Intermittent Hypoxia (MIH) - 15% O2 for 1 h/day, 5 days/week for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C) - 21% O2 for 1 h/day, 5 days/week for 4 weeks
Number of subjects: 30
Study: 15848979

Group type: EXPERIMENTAL
Intervention: Stabilization appliance (group T)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control appliance (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mixed group (group M)
Number of subjects: 60
Study: 11484097

Group type: EXPERIMENTAL
Intervention: 2-year exercise training
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 1-year exercise training plus 1-year detraining
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 9495424

Group type: COMPARATOR
Intervention: Epidural opioids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epidural local anesthetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intercostal nerve blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surrogate measures of pulmonary function (FEV1, FVC, PEFR)
Number of subjects: 0
Study: 8067649

Group type: EXPERIMENTAL
Intervention: Mailed educational materials coupled with a simulated patient instructor office visit
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Mailed educational materials only
Number of subjects: 757

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Combined intervention group
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Educational materials only
Number of subjects: 757

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 757
Study: 3149771

Group type: EXPERIMENTAL
Intervention: 1.2 mg scopolamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30999554

Group type: EXPERIMENTAL
Intervention: AA mixture containing 3600 mg of arginine, 2200 mg of valine, and 200 mg of serine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: AA mixture
Number of subjects: 39
Study: 28678853

Group type: EXPERIMENTAL
Intervention: Generic alendronate (Bonmax®) 70 mg/week
Number of subjects: 140

Group type: COMPARATOR
Intervention: Brand alendronate (Fosamax®) 70 mg/week
Number of subjects: 140
Study: 24699438

Group type: EXPERIMENTAL
Intervention: High background rhythm frequency (BRF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More than median theta (θ) band power
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low background rhythm frequency (BRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less than median theta (θ) band power
Number of subjects: 0
Study: 23535090

Group type: EXPERIMENTAL
Intervention: Antihistamines
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combined antihistamines and leukotriene antagonists
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 65
Study: 21638013

Group type: EXPERIMENTAL
Intervention: 1-Hz cerebellar repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 20
Study: 19383112

Group type: EXPERIMENTAL
Intervention: 44% oxygen (hyperoxia)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 51
Study: 16704575

Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Deadspace (DS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10
Study: 15033131

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight reduction program
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral weight reduction program + CPAP
Number of subjects: 31
Study: 11835741

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO), 3 courses of treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Dehydrating, cortical steroid and antibiotic therapy (Control)
Number of subjects: 55
Study: 9491904

Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: PMMA membrane
Number of subjects: 10